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PI3K and PTEN lipid phosphatase control the level of
cellular phosphatidylinositol (3,4,5)-trisphosphate,
an activator of AKT kinases that promotes cell
growth and survival. Mutations activating AKT are
commonly observed in human cancers. We report
here that ENTPD5, an endoplasmic reticulum (ER)
enzyme, is upregulated in cell lines and primary
human tumor samples with active AKT. ENTPD5
hydrolyzes UDP to UMP to promote protein N-glyco-
sylation and folding in ER. Knockdown of ENTPD5 in
PTEN null cells causes ER stress and loss of growth
factor receptors. ENTPD5, together with cytidine
monophosphate kinase-1 and adenylate kinase-1,
constitute an ATP hydrolysis cycle that converts
ATP to AMP, resulting in a compensatory increase
in aerobic glycolysis known as the Warburg effect.
The growth of PTEN null cells is inhibited both
in vitro and in mouse xenograft tumor models.
ENTPD5 is therefore an integral part of the PI3K/
PTEN regulatory loop and a potential target for anti-
cancer therapy.
INTRODUCTION
Class I phosphatidylinositol 3-kinases (PI3Ks) and lipid phospha-
tase PTEN balance cellular response to growth and survival
signals (reviewed by Engelman et al., 2006). In response to acti-
vation of receptor tyrosine kinases, PI3K phosphorylates phos-
phatidylinositol 4,5-bisphosphate (PIP2) at the 3-OH position of
the inositol ring to generate phosphatidylinositol 3,4,5-trisphos-
phate (PIP3) that recruits and activates serine/threonine kinase
AKT (Whitman et al., 1988; Franke et al., 1997; Stephens et al.,
1998). AKT subsequently activates many downstream targets
for cell growth and survival, including the rapamycin-sensitive
mTOR complex 1 (mTORC1), which then phosphorylates
p70S6K and translation initiation factor 4E-BP1 to accelerate
the translational rate, thus accommodating rapid growth (Fingaret al., 2002). PTEN, by dephosphorylating PIP3 back to PIP2,
antagonizes the signal generated by PI3K (Maehama and Dixon,
1998). The importance of the PI3K/PTEN pathway has been
manifested by frequent PI3K gain of function, or PTEN loss of
function, in a variety of human cancers (reviewed by Yuan and
Cantley, 2008; Keniry and Parsons, 2008).
AKT activation also contributes to the elevation of aerobic
glycolysis seen in tumor cells, known as the Warburg effect
(Elstrom et al., 2004; Warburg, 1925). AKT promotes cell-surface
expression of glucose transporters while sustaining activation of
hexokinase and phosphofructose kinase-1 (PFK1), thus acceler-
ating influx and capture of glucose for glycolysis (reviewed by
Vander Heiden et al., 2009). Of interest, in cancer cells, there is
invariant expression of the embryonic M2 splice version of pyru-
vate kinase, an enzyme working in the last step of glycolysis,
instead of a more active M1 splicing isoform expressed in
most of the adult tissues (Christofk et al., 2008). The combined
effects of more glucose entering into the glycolysis pathway
and slowing down pyruvate kinase activity build up intermediate
metabolites for synthesis of growth-enabling macromolecules.
One noticeable example is the entry of glucose-6-phosphate
to the pentose shunt pathway to generate ribose for nucleotide
synthesis (reviewed by Vander Heiden et al., 2009).
Another outlet of glucose-6-phosphate is to form UDP-
glucose, a substrate for protein glycosylation. In mammalian
cells, most secreted proteins and membrane proteins are glyco-
sylated at the asparagine (Asn) sites, i.e., N-glycosylated. Of
interest, receptor tyrosine kinases that promote cell growth
and proliferation, such as the epidermal growth factor receptor,
EGFR, are much more highly N-glycosylated than receptors
whose functions do not (Lau et al., 2007). Most of the glycosyla-
tion reactions happen in the Golgi apparatus, with two known
exceptions. One is the dolichol-linked 14 sugar core glycan
(Glc3Man9GlcNAc2) that is synthesized in cytoplasm and ER
membrane before being flipped into the lumen of ER, where it
is transferred to the Asn of the nascent polypeptide chain (re-
viewed by Helenius and Aebi, 2004). Another is reglucosylation
in ER after the third and second glucose (Glc) on the core glycan
are trimmed by glycosidase I and II. Trimming and reglucosyla-
tion by UDP-glucose:glycoprotein glucosyltransferase (UGGT)
generate monoglucosylated structures that are recognized byCell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc. 711
calnexin/calreticulin, an ER molecular chaperone system for
N-glycosylated proteins (reviewed by Ellgaard et al., 1999).
The removal and addition of glucose allow the binding and
release of calnexin/calreticulin to and from nascent polypeptide
chains until the proteins are correctly folded and transferred to
Golgi for further glycosylation. If proteins are misfolded beyond
repair, they are subjected to degradation by the ER-associated
protein degradation system (ERAD) (reviewed by Fewell et al.,
2001).
During a study using the embryonic fibroblasts (MEFs) from
the PTEN null mice and PTEN heterozygous littermates (Stam-
bolic et al., 1998), we made a surprising finding that an ER
UDP hydrolysis enzyme is upregulated by AKT activation. This
enzyme, ENTPD5, seems to mediate many of the observed
cancer-related phenotypes associated with AKT activation.
RESULTS
PTEN Knockout MEFs Have an Elevated Activity that
Hydrolyzes ATP to AMP
As reported previously, the PTEN null MEFs showed elevated
levels of phosphorylated AKT and p70S6 kinase, whereas the
total protein level of these two kinases remained the same as
in PTEN heterozygous MEFs (Stambolic et al., 1998) (Figure 1A).
We noticed that S-100 cell extracts (prepared after collecting the
supernatants of 100,0003 g spin of broken cells) from PTEN null
MEFs had a lower ATP level compared to that from the heterozy-
gous MEFs (Figure 1B, columns 7 and 8). Given that cellular ATP
levels are relatively stable, we reasoned that the difference in
their ATP contents occurred during S-100 preparation, which
took about 1 hr. Indeed, as shown in Figure 1B, the ATP levels
in PTEN null MEFs were only slightly lower than those in the
heterozygousMEFs if the measurement was carried out immedi-
ately after cells were harvested (Figure 1B, columns 1 and 2).
When the broken cell suspension, or supernatants after
10,000 3 g spin (S-10), or S-100 were incubated on ice for 1 hr
before the ATP levels were measured, ATP concentrations in
the extracts from PTEN knockout MEFs were much lower than
those from heterozygous MEFs (Figure 1B, columns 3–8). Such
an observation indicated that there was higher ATP hydrolysis
activity in the PTEN knockout cell extracts. To measure this
activity directly, we incubated a-P32-ATPwith the S-100 extracts
and analyzed the radioactivity using thin layer chromatography.
As shown in Figure 1C, more radiolabeled ATP was hydrolyzed
when incubated with the S-100 from PTEN null MEFs, and the
nucleotide was hydrolyzed all the way to AMP.
To sort out whether the accelerated ATP hydrolysis was due to
a specific activity or a combination of nonspecific ATPases, we
fractioned the same amount of S-100 extracts from PTEN null
and PTEN heterozygous MEFs side by side on a Q Sepharose
ion-exchange column. The fractions from each column run
were dialyzed, and ATPase activity was measured by adding
each column fraction to the S-100 from PTEN heterozygous
MEF, which served as the baseline activity. A single peak of
elevated ATP-to-AMP activity centered at fractions 11–13 was
observed in fractionated S-100 from PTEN null MEFs, whereas
much less activity was seen in the corresponding fractions
from PTEN heterozygous MEFs (Figure 1D).712 Cell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc.ENTPD5 Is Responsible for the Elevated ATPase Activity
in PTEN Knockout Cells
Wedecided to purify the ATPase from large-scale cultured PTEN
knockout MEFs. We took 800 mg of S-100 from PTEN null MEFs
and put it through five chromatographic steps (Figure 2A). The
ATP hydrolysis activity was measured as in Figure 1D, and the
active fractions from each column step were pooled, dialyzed,
and loaded onto the next column. Finally, after a Superdex 200
gel-filtration column, the active fractions were loaded onto
a 100 ml Mini Q column and the bound protein was eluted with
a linear salt gradient. Fractions of 100 ml were collected and as-
sayed. Shown in Figure 2B, a single ATP hydrolysis peak
centered at fraction 6 was observed. When these fractions
were analyzed by SDS-PAGE followed by silver staining,
a protein band just below the 50 kDa molecular weight marker
correlated perfectly with the activity.
This protein was excised from the gel and subjected to mass
spectrometry analysis. The enzyme was identified as ectonu-
cleoside triphosphate diphosphohydrolase 5, ENTPD5, a mem-
ber of the ENTPD enzyme family known to hydrolyze tri- and/or
diphospshonucleotide to monophosphonucleotide (reviewed
by Robson et al., 2006).
To verify that ENTPD5 is indeed the enzyme that caused the
higher rate of ATP-to-AMP conversion in PTEN null MEFs, we
first did a western blotting analysis of ENTPD5 in these MEFs.
As shown in Figure 2C (bottom), ENTPD5 was only prominently
detected in PTEN null extracts, but not in PTEN heterozygous
extracts (Figure 2C, lanes 1 and 2). When mouse ENTPD5 was
exogenously expressed in the PTEN heterozygous MEFs, the
extracts from these cells showed the ability to hydrolyze ATP
to AMP just like that from PTEN null cells (Figure 2C, lanes
3–5). Moreover, when ENTPD5 was knocked down in PTEN
null MEFs with two different siRNA oligos, the ATP-to-AMP
conversion was diminished in each case, and a control siRNA
oligo had no effect (Figure 2C, lanes 6–10).
Toconfirmthat theelevated level ofENTPD5 isdue todeletionof
PTEN, we transfected a wild-type PTEN cDNA, or the phospha-
tase active site mutant (PTEN C124S), into PTEN null MEFs.
Indeed, restoring PTEN expression in these cells lowered phos-
phoAKTanddiminishedENTPD5expression,whereas thecatalyt-
ically dead mutant PTEN had no effect (Figure 2D, lanes 2 and 3).
Consistently, treatment of PTENnullMEFswith a PI3 kinase inhib-
itor also lowered the level of ENTPD5 (Figure 2E, lanes 2 and 3).
The upregulation of ENTPD5 in PTEN null cells is at transcrip-
tional level. Its mRNA is 6-fold higher in PTEN null MEFs
compared to that in PTEN heterozygous MEFs (Figure S1 avail-
able online). The promoter region of ENTPD5 is negatively regu-
lated by the FoxO family of transcription factors (Figure S2),
which upon phosphorylation by AKT, are displaced from the
nucleus into the cytoplasm (Brunet et al., 1999).
To directly demonstrate the nucleotide hydrolysis activity of
ENTPD5, we generated recombinant human ENTPD5 protein
in insect cells using a baculovirus vector and purified the enzyme
to homogeneity (Figure 3A, right). The purified enzyme was then
incubated with ATP, ADP, CTP, CDP, GTP, GDP, UTP, and UDP,
and the released phosphate was measured. Unexpectedly, the
purified recombinant ENTPD5 could only hydrolyze UDP and
GDP (Figure 3A, left).
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Figure 1. Identification of ATP Hydrolysis Activity in PTEN Knockout MEF Cells
(A) Total cell extracts from PTEN+/ and PTEN/ cells were prepared as described in Experimental Procedures. Aliquots of 10 mg protein were subjected to 10%
SDS-PAGE followed by western analysis of PTEN (asterisk denotes a cross-reactive band), phosphorylated AKT (pAKT), AKT, phosphorylated P70S6 kinase
(pP70S6K), P70S6 kinase, and b-actin.
(B) Cell extracts were prepared from PTEN+/ and PTEN/ cells, and at indicated steps of preparation, aliquots of 20 ml samples were incubated on ice for 1 hr
followed by immediate measurement of ATP using a Cell Titer-Glo kit. Error bar represents standard deviation of two independent experiments.
(C) Aliquots of 30 mg of S-100 fractions from PTEN+/ or PTEN/ cells were incubated with a-P32-labeled ATP and analyzed by TLC as described in the
Experimental Procedures. Positions for ATP, ADP, or AMP were indicated.
(D) 6 ml each of S-100 from PTEN+/ or PTEN/ cells (3.5 mg/ml) was separated by a 1 ml Q Sepharose HP column with a salt gradient elution as indicated.
Fractions of 1 ml were collected and dialyzed overnight at 4C. 10.5 ml of each fraction was mixed with another 10.5 ml of undialyzed S-100 from PTEN+/ cells
and assayed for ATP hydrolysis activity as in (C). The positions of ATP, ADP, and AMP were indicated. FPLC histograms were presented in top panels.UMP or GMP Is a Required Cofactor
for the ATP Hydrolysis Activity
During our ENTPD5 purification efforts, we noticed that a small
molecule cofactor was required for the observed ATP-to-AMP
hydrolysis activity. S-100 extracts from PTEN null MEFs lostATP-to-AMP converting activity after dialysis (Figure 3B,
lane 4), and the activity was restored with addition of a small
molecule fraction prepared by a 10 kDa cutoff filter (Figure 3B,
lane 6). There was no difference in such a small molecule in
PTEN heterozygous and PTEN null MEFs (Figure 3B, lanes 6Cell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc. 713
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Figure 2. Purification and Characterization of ENTPD5
(A) Diagram of the purification scheme for ATP hydrolysis activity from S-100 of PTEN/ MEF cells.
(B) Final step of purification. (Top) Aliquots of 30 ml of indicated fractions from theMini Q columnwere subjected to 4%–10%gradient SDS-PAGE gels followed by
staining using a silver staining kit from Invitrogen. (Bottom) Aliquots of 3 ml of indicated fractions were incubated with 10.5 ml of undialyzed S-100 from PTEN+/
MEF cells and assayed for ATP hydrolysis activity.
(C) (Lanes 1–5) ATP hydrolysis activity in S-100 from PTEN+/ MEF cells expressing exogenous ENTPD5. PTEN+/ vector or PTEN+/ ENTPD5 1# and 2# (two
individual clones with different expression levels of ENTPD5) were established as described in the Experimental Procedures. Cell lysates (S-100) from indicated
cell lines were prepared, and aliquots of 30 mg were used for ATP hydrolysis assay. (Lanes 6–10) ENTPD5 expression in PTEN/MEFs was knocked down as
described in the Experimental Procedures. The cells were harvested, and S-100 were prepared and normalized for ATP hydrolysis assay. Positions of ATP, ADP,
and AMP are indicated. (Bottom) Aliquots of 10 mg protein of indicated samples were subjected to 10% SDS-PAGE followed by western analysis of ENTPD5.
Asterisk denotes cross-reactive proteins.
(D) PTEN/MEF cells were transfected with 4 mg plasmid DNA containing vector control or cDNA encoding PTEN or PTENcs as indicated. At 24 hr after trans-
fection, cells were harvested and total cell lysates were prepared. Aliquots of 10 mg of protein were loaded onto 10% SDS-PAGE followed by western analysis of
levels of PTEN, AKT, phosphorylated AKT(pAKT), ENTPD5, and b-actin as indicated.
(E) PTEN+/ and PTEN/ MEF cells were treated with DMSO or LY294002 (50 mM) for 24 hr. Aliquots of 20 mg total cell extracts were subjected to 10% SDS-
PAGE followed by western analysis using indicated antibodies.
See also Figure S1 and Figure S2.and 8), and the molecule was also present in S-100 from HeLa
cells (Figure 3B, lane 10), which have a wild-type PTEN.
Based on its biochemical properties, we deduced that the
cofactor is a nucleotide. Testing a variety of nucleotides revealed
that uracil and guanine, either in tri-, di-, or monophosphate
form, substituted the small molecule fraction from cells714 Cell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc.(Figure 3C, lanes 1–15). In contrast, thymidine nucleotides
have no activity, whereas CMP only showed a slight activity.
To see whether the conversion of UTP/UDP to UMP is neces-
sary for the observed activity, we tested various forms of
nonhydrolyzable uracil, including UTPgS, UTPaS, and UMP-
PNP (Figure 3D). All of these nucleotides worked except UTPaS,
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Figure 3. Small Molecule Requirement for ENTPD5-Mediated ATP Hydrolysis
(A) (Right) the recombinant human ENTPD5 was generated and purified as described in the Experimental Procedures. An aliquot of 120 ng recombinant ENTPD5
was subjected to SDS-PAGE followed by Coomassie brilliant blue staining. Arrows indicate recombinant ENTPD5. (Left) The nucleotide hydrolysis reactions were
carried out in triplicate by mixing 0.1 mg/ml ENTPD5 with 50 mM indicated nucleotides. After 2 hr incubation at 30C, released free phosphate was measured by
malachite green assay as described in the Experimental Procedures. Data shown are representative of three independent experiments. Error bars indicate SEM.
(B) Small molecule (<10 kDa) was extracted from either PTEN+/ or PTEN/MEF cells or HeLa S3 cell lysates (S-100 fractions) as described in the Experimental
Procedures. Aliquots of 10.5 ml undialyzed cell lysates (lane 1 and 2) or dialyzed cell lysates (lane 3–10) fromPTEN+/ (lanes 1, 3, 5, 7, and 9) orPTEN/ (lanes 2, 4,
6, 8, 10) MEFs (3.5 mg/ml) were mixed with another 10.5 ml buffer A (lane 1 to 4) or small molecule recovered from PTEN+/ (lanes 5 and 8), PTEN/ cells (lanes 6
and 7), or from HeLa S3 cells (lanes 9 and 10) and were assayed for ATP hydrolysis activity. The positions of ATP, ADP, and AMP were indicated.
(C) Aliquots of 10.5 ml dialyzed S-100 from PTEN/MEF cells (3.5mg/ml) were incubated in the presence of indicated final concentration of UTP, UDP, and UMP;
or GTP, GDP, and GMP; or CTP, CDP, and CMP; or TTP, TDP, and TMP as indicated at 30C with a-P32-labeled ATP in a total volume of 30 ml at 30C for 1 hr
followed by TLC to resolve radioactive adenosine nucleotides. Position of AMP on TLC plate is indicated.
(D) Aliquots of dialyzed S-100 prepared from PTEN/MEF cells were mixed with buffer A (lane 1) or indicated final concentration of indicated nucleotides and
assayed for ATP hydrolysis activity.
See also Figure S3.which could not be hydrolyzed to UMP, indicating that the
conversion to UMP is critical for this cofactor to function. The
same holds true for guanine nucleotides (Figure S3).
UMP, ENTPD5, UMP/CMP Kinase-1, and Adenylate
Kinase-1 Constitute an ATP-to-AMP Hydrolysis Cycle
Based on the facts that purified ENTPD5 is unable to hydrolyze
ATP directly and the assay also contained S-100 from PTENheterozygous MEFs, we realized that there must bemore factors
in the S-100, which are also required to hydrolyze ATP to AMP.
These factors presented in cells regardless of their PTEN status.
For example, when we added purified, recombinant ENTPD5
and UMP to the dialyzed S-100 from large-scale cultured HeLa
cells, the ATP-to-AMP hydrolysis was reconstituted (Figure 4A,
lanes 1–6). This observation made purification of these factors
easier because HeLa cells can be grown in large quantity inCell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc. 715
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Figure 4. Reconstitution of ENTPD5-Mediated ATP Hydrolysis
(A) HeLa S3 cell S-100 was fractionated by Q Sepharose column to two fractions (Q-FL [flowthrough] and Q-30). Q-30 represents fraction eluted with 300 mM
NaCl. Aliquots of 15 ml buffer A (lane 1 and 2), or dialyzed HeLa cell S-100 (lanes 3–6), or Q-FL (lanes 7–10), or Q-30 (lanes 11–14), or Q-FL combined with Q-30
(7.5 ml each) (lanes 15–18) weremixedwith (lanes 1, 2, 4, 6, 8, 10, 12, 14, 16, and 18) or without (lanes 3, 5, 7, 9, 11, 13, 15, and 17) ENTPD5 in the presence (lanes 2,
5, 6, 9, 10, 13, 14, 17, and 18) or absence (lanes 1, 3, 4, 7, 8, 11, 12, 15, and 16) of 100 mM UMP and assayed for ATP hydrolysis activity.
(B) (Left) Diagram of the purification scheme for the required factor in Q-30. (Right) Final step of purification of CMPK1. (Top) Aliquots of 60 ml indicated Mini Q
fractions that were subjected to 4%–10% gradient SDS-PAGE followed by silver staining. Arrow indicates the protein band correlated with ATP hydrolysis
activity. (Bottom) Aliquots of 5 ml indicated fractions that were mixed with 15 ml of dialyzed Q-FL fraction in the presence of 100 mMUMP and 18 ng recombinant
ENTPD5 and were assayed for ATP hydrolysis activity.
(C) 3 ml of the Q-FL fraction was concentrated to 600 ml with a spin column and analyzed on a Supdex-200 column (10/30). Fractions of 1 ml were collected, and
aliquots of 7.5 ml of indicated fractionswere combinedwith 7.5 ml dialyzedQ-30 fraction, 100 mMUMP, and 18 ng recombinant ENTPD5 andwere assayed for ATP
hydrolysis activity. Positions of radioactive ATP, ADP, and AMP are indicated. (Bottom) Aliquots of 10 ml of indicated fractions were subjected to 10%SDS-PAGE
followed by western blotting analysis using an antibody against human adenylate kinase 1 (AK1).
(D) (Left) Aliquots of recombinant AK1 (lane 1), ENTPD5 (lane 2), and CMPK1 (lane 3) (final concentration, 1 mg/ml) were incubated alone or were sequentially
combined as indicated (lane 4 to 8) in the presence (lane 1 to 7) or absence (lane 8) of UMP (100 mM) for ATP hydrolysis activity. Position of ATP, ADP, or
AMP was indicated. (Right) Aliquots of 10 mg recombinant AK1 (lane 9), ENTPD5 (lane 10) or ENTPD5 pretreat with PNGase F (NEB) (50 units/mg ENTPD5)
(lane 11), and CMPK1 (lane 12) were subjected to 10% SDS-PAGE followed by Coomassie brilliant blue staining.suspension. To identify these factors, we fractionated HeLa cell
S-100, using a Q Sepharose column, and collected both the
flowthrough (Q-FL) and column-bound fractions eluted with
300 mM NaCl (Q-30). Neither fraction alone was able to hydro-
lyze ATP to AMP, although the Q-30 fraction, when ENTPD5
and UMPwere present, hydrolyzed ATP to ADP (Figure 4A, lanes
13 and 14). When both the Q-FL and Q-30 fractions were
included, the ATP-to-AMP activity was fully reconstituted (Fig-
ure 4A, lane 18).
We purified the activity present in the Q-30 fraction. The
activity present in the Q-30 fraction was purified by subjecting716 Cell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc.HeLa S-100 onto four sequential column chromatographic steps
and finally onto a Mini Q column (Figure 4B, left). The activity
was eluted from this column with a linear salt gradient from 40
to 120 mM NaCl, and fractions eluted from the column were as-
sayed in the presence of recombinant ENTPD5, UMP, and the
Q-FL fraction (Figure 4B, right-bottom). A peak of activity was
observed at fractions 8–10. The same fractions were subjected
to SDS-PAGE followed by silver staining, and two protein bands
close to 37 and 20 kDa markers correlated perfectly with activity
(Figure 4B, right-top). Both bands were identified by mass
spectrometry as human UMP/CMP kinase-1 (CMPK1).
The identification of UMP/CMP kinase in the Q-30 fraction
shed light on why UMP is a cofactor for the ATPase activity
and how ENTPD5 plus this enzyme generates ADP from ATP.
In this reaction, UMP is phosphorylated into UDP by CMPK1
and ATP, generating ADP. UDP is subsequently hydrolyzed by
ENTPD5 to UMP, completing the cycle with net conversion of
ATP to ADP.
With this knowledge,we thenmadeaneducatedguess that the
third protein factor present in the Q flowthrough fraction should
be an adenylate kinase, which converts two ADP into one ATP
and AMP, causing the ATP-to-AMP conversion seen in PTEN
null cell extracts. To confirm this, we took theQ flowthrough frac-
tion and subjected it to a gel-filtration column and collected the
fractions eluted from the column to assay for ATP-to-AMPhydro-
lysis in the presence of UMP, purified recombinant ENTPD5, and
the Q-30 fraction that contains CMPK1. An ATP-to-AMP activity
peak centered at fractions 17 and 18 was observed (Figure 4C,
top). When these factions were subjected to western blotting
analysis using an antibody against adenylate kinase-1 (AK1),
the detected western blotting band correlated perfectly with the
activity peak (Figure 4C, bottom). The correlationwasmaintained
with additional chromatographic steps (data not shown).
We subsequently generated recombinant CMPK1 and AK1 in
bacteria and purified them to homogeneity (Figure 4D, lanes 9
and 12). Purified recombinant ENTPD5 expressed in insect cells
runs as a triplet on an SDS-PAGE gel that could be shifted down
to a doublet after treatment by PNGase F, indicating that
ENTPD-5 is glycosylated (Figure 4D, lanes 10 and 11).
These purified recombinant proteins allowed us to reconsti-
tute the ATP-to-AMP hydrolysis cycle. Only when all three
enzymes and UMP were present, efficient ATP-to-AMP conver-
sion was observed (Figure 4D, lanes 1–8).
ENTPD5 Is an ER Enzyme
After purification and identification of ENTPD5 from PTEN null
cells, we realized that ENTPD5 is identical to a previously purified
ER UDPase (Trombetta and Helenius, 1999). Although we iden-
tified and purified ENTPD5 from the S-100, the enzyme most
likely fractionated there as a result of broken ER from physical
shearing during the cell-breaking process. When we expressed
an ENTPD5-GFP fusion protein in cells, the GFP signal was co-
localized with the coexpressed ER-DsRed marker (Figure 5A).
The ER location of ENTPD5 and its preferred specificity for
UDP suggested that ENTPD5 functions in the process of reglu-
cosylation catalyzed byUGGT for calnexin/calreticulin-mediated
protein folding (Trombetta and Parodi, 2003). In the process,
UDP is generated after the conjugated glucose gets transferred
to the glycosidase I/II trimmed core glycan on N-glycosylated
proteins. UDP-glucose is made in cytosol and transported into
ER through the UDP-sugar transporter, which is an antiporter
that must exchange out one molecule of UMP for each UDP
sugar conjugate imported into the ER (Hirschberg et al., 1998).
UDP therefore needs to be hydrolyzed to UMP to prevent end
product feedback inhibition of UGGT, as well as to serve as
a substrate for the antiporter (Trombetta and Helenius, 1999).
UMP is phosphorylated back to UDP by CMPK1 in the cytosol,
and the generated ADP is converted to ATP and AMP by AK1
(diagramed in Figure 5B).Knockdown of ENTPD5 Causes ER Stress and Growth
Inhibition
Because cells with an activated PI3K/AKT pathway increase
their cellular protein translation level, cells need to evolve a corre-
sponding system in ER to accommodate the high demand for
protein folding process. It is possible that cells may do so by up-
regulating ENTPD5 to increase the conversion of UDP to UMP in
ER, thereby promoting N-glycosylation and folding. Thus,
reducing the level of ENTPD5 in cells with active AKT should
induce ER stress. In addition, because many growth-promoting
cell membrane receptors are highly N-glycosylated, loss of
function of ENTPD5 could affect their folding process, resulting
in their reduction and, subsequently, cell growth arrest. To test
this hypothesis, we engineered several cell lines based on
the PTEN null MEFs in which the expression of ENTPD5 could
be knocked down with the addition of doxcycline (Dox),
which turned on a Tet-suppressor-controlled shRNA-targeting
ENTPD5. The results from a representative cell line were shown
in Figure 5C. Comparing to PTEN null MEFs expressing GFP
shRNA, addition of Dox to the culture media resulted in success-
ful knockdown of ENTPD5 expression in these cells. As a result,
an ER stress marker, GRP78/BiP, was induced, and cellular
N-glycosylation level, as measured by PHA blotting, was down
(Figure 5C, lanes 5–8). Of interest, the levels of receptor tyrosine
kinases, including EGFR, Her-2/Erb-2, and type I insulin-like
growth factor receptor (IGF-IR) b, were significantly decreased
after ENTPD5 knockdown.
To confirm that the above-mentioned cellular effects after
ENTPD5-targeting shRNA expression were specific, we intro-
duced into these cells a cDNA encoding ENTPD5 with silent
mutations in the shRNA target sequence. In these cells, although
the endogenous ENTPD5 was still knocked down after addition
of Dox (Figure 5D, lanes 2, 4, and 6), the expression of an
shRNA-resistant wild-type transgene (three flag tags were fused
to ENTPD5 coding sequence so it migrated higher) led to
complete reversal of BiP induction, lowered glycosylation, and
downregulation of these growth factor receptors (Figure 5D,
lane 4). In contrast, introducing an E171A mutant that abolishes
UDP hydrolysis activity of ENTPD5 was not able to rescue these
phenotypes (Figure 5D, lane 6). In addition to BiP, another ER
stress marker, CHOP, was also induced when ENTPD5 was
knocked down (Figure 5D).
Consistent with the loss of growth factor receptors after
ENTPD5 knockdown, cell growth was also dramatically attenu-
ated. As shown in Figure 5E, when ENTPD5 in PTEN null MEFs
was knocked down after addition of Dox, very few colonies
grew on the culture dish after 10 days, although the same
number of cells was plated initially, and they were cultured under
the same condition (Figure 5E, left row). The growth inhibition
was rescued when the shRNA-resistant ENTPD5 cDNA was ex-
pressed (Figure 5E, middle row), whereas the inhibition was
exacerbated if an enzymatic dead mutant of ENTPD5 was ex-
pressed instead (Figure 5E, right row).
ENTPD5 Promotes Aerobic Glycolysis
One implication of elevated ENTPD5 expression is that a
significant percentage of cellular ATP is consumed through
the ENTPD5/CMPK1/AK1 enzyme cascade. To maintain theCell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc. 717
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Figure 5. Biological Function of ENTPD5 in PTEN/ MEF Cells
(A) PTEN/MEF cells were cotransfected with mouse ENTPD5-GFP and free DsRed or with ENTPD5-GFP and ER-localized DsRed (ER-DsRed). ENTPD5-GFP
colocalized with ER-DsRed (bottom row), but no obvious codistribution with free DsRed was observed (top row). Scale bars, 10 mm.
(B) Working model for ENTPD5. See the text for details.
(C) PTEN/MEF cells with doxycycline (Dox)-inducible expression of shRNA-targeting ENTPD5 was generated as described in the Experimental Procedures.
After 2 or 4 days induction with Dox (0.125 mg/ml), cells were harvested and total cell lysates were prepared as described in the Extended Experimental Proce-
dures. Aliquots of 10 mg protein were subjected to SDS-PAGE followed by western blotting analysis using the indicated antibodies. Glycosylation was visualized
by PHA blot as indicated. Asterisk denotes decreased glycosylated proteins.
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intracellular ATP level, the extra ATP consumed should come
from either increased oxidative phosphorylation or glycolysis.
We therefore tested both by measuring oxygen consumption
and lactate production, respectively. Consistent with previous
reports, there was not much difference in the respiration rate of
PTEN null and PTEN heterozygous MEFs (Figure S4), but
PTEN null cells showed 40% higher lactate production in their
cultured medium (Figure 6A, columns 4 and 5). When ENTPD5
was ectopically expressed in two PTEN heterozygousMEF lines,
lactate production was increased, and the level of increase
correlated with that of ENTPD5 expression (Figure 6A, columns
2 and 3). Consistently, when ENTPD5 was knocked down with
addition of Dox as in Figure 5D, lactate production was signifi-
cantly decreased (Figure 6B, columns 1 and 2). In PTEN null
MEFs harboring Dox-inducible ENTPD5-targeting shRNA that
also expressed shRNA-resistant ENTPD5 transgene, addition
of Dox did not result in a decrease in lactate production, and
the basal lactate production also became higher, correlated
with the higher than endogenous expression of the transgene
(Figure 6B, columns 3 and 4, and Figure 5D). In contrast, when
the catalytic site mutant ENTPD5 transgene was expressed to
the similar level, lactate production still reduced with the addition
of Dox (Figure 6B, columns 5 and 6).
If the ATP hydrolysis cycle initiated by ENTPD5 discovered
in vitro is operational in cells, and the extra ATP consumed by
a higher level of ENTPD5 is compensated by increased glycol-
ysis, glucose starvation of these cells should result in much
faster decrease of intracellular ATP level compared to cells
with lower ENTPD5 expression. Indeed, when intracellular ATP
concentrations in PTEN heterozygous and PTEN null MEFs
were measured after glucose withdrawal from the culture media,
that in PTEN null MEFs decreased to about half of the original
level within the first hour, while there was little change of ATP
in PTEN-heterozygous MEF within 2 hr (Figure 6C).
To confirm that the faster ATP level dropping in PTEN null cells
was due to higher expression of ENTPD5, the same set of MEFs
as in Figure 6B was subjected to glucose starvation after
ENTPD5 was knocked down with the addition of Dox. Knock-
down of ENTPD5 for 2 days in PTEN null MEFS caused the total
cellular ATP level to decrease (Figure 6D, columns 3 and 4).
However, the ATP level did not decrease further after glucose
starvation for 1 hr, whereas cells without Dox treatment
consumed 50% of original ATP during this period (Figure 6D,
columns 1 and 2). The MEFs expressing the shRNA-resistant
ENTPD5 did not lower their ATP level with Dox treatment, but
their ATP levels were evenmore drastically lowered after glucose
starvation, possibly due to ENTPD5 overexpression (Figure 6D,
columns 5–8). In contrast, cells expressing a similar level of the
catalytic dead mutant ENTPD5 behaved the same as cells
without transgene expression (Figure 6D, columns 9–12).
The observed decrease of glycolysis after ENTPD5 knock-
down could be due to lowered tyrosine kinases receptors and(D) Rescue cell lines with expression of shRNA-resistant wild-type or catalytic d
Experiments Procedures. Same as in (C), after 2 days culture, cells were harves
by western analysis as indicated. Glycosylation was visualized by PHA blot anal
(E) Rescue cell line was plated at density of 53 104/100 mmdish and treated with
plates were stained by methylene blue.AKT activity (Figure 5C and Figure S5), which stimulates the
glucose transporter activity on cell surface (Kohn et al., 1996;
Plas et al., 2001). In addition, knockdown of ENTPD5may reduce
the production of ADP/AMP, which allosterically activate glycol-
ysis enzymes such as phosphofructose kinase (PFK) (Gevers
and Krebs, 1966). To distinguish these possibilities, cellular
fructose-6-phosphate and fructose-1,6-bisphosphate were
measured using LC-Mass. As shown in Figure 6E, the former
was lowered by 20% after ENTPD5 knockdown (Figure 6E,
left), whereas the latter dropped by 60% (Figure 6E, right).
These results suggested that ENTPD5 indeed affects glucose
influx to cells, but its major impact on glycolysis is to directly
activate glycolysis enzymes such as PFK by hydrolyzing ATP.
ENTPD5 Expression Correlates with AKT Activation in
Human Cancer Cell Lines and Primary Tumor Samples
PTEN mutation and AKT activation are common features for
human cancer. To check whether what was observed in PTEN
null MEFs is also true for human cancer cells, we screened
a panel of human cancer cell lines for the expression of PTEN,
activated AKT, and ENTPD5. As shown in Figure 7A, AKT activa-
tion was seen in human prostate cancer lines C42 and LNCaP
cells, and in these two cell lines, elevated ENTPD5 expression
was also observed.
We also examined ENTPD5 expression and AKT activation in
primary human tumor samples by staining two adjacent sections
from a formalin-fixed, paraffin-embedded human primary pros-
tate cancer sample with rabbit monoclonal antibodies against
human ENTPD5 and phosphoAKT, respectively. The specificity
of this anti-ENTPD5 antibody was verified by western blotting
analysis using LNCaP cell lines with or without their ENTPD5
knocked down (Figure S6A). The staining intensity for ENTPD5
in tumorwas significantly greater comparedwith adjacent normal
tissue and was correlated with pAKT staining (Figure 7B). Out of
10 samples frompatients between age 57 and 76, only one tumor
sample from a 57-year-old patient and another sample collected
from a patient who had just gone through therapy did not show
strongENTPD5staining, and the same tumorswerealsonegative
for pAKT (Figure S6B2 and Figure S6B10). The remaining eight
samples all showed greater tumor staining of pAKT and ENTPD5
(Figure 7B and Figures S6B3–S6B9).
Because microarray data of many tumors are publicly avail-
able, we also analyzed a group of recently publicized microarray
data from human prostate cancer samples (Bermudo et al.,
2008). We found that ENTPD5 is highly expressed in all 20 tumor
samples compared to normal prostate epithelium cells (Fig-
ure S7). In addition, after clustering all gene expression profiles
from prostate tumor microarray data using SOM (self-organiza-
tion method), we identified dozens of genes associated with
AKT activation, including Her-3, PI3KCB, Ras, S6 kinase,
CD36, IL8, EGF, osteropontin, and FoxO1, which are signifi-
cantly coregulated with ENTPD5 (Figure S7).ead mutant (E171A) ENTPD-5 were established as described in the Extended
ted, and total cell lysates (10 mg/lane) were subjected to SDS-PAGE followed
ysis.
Dox as in (C). Cell medium was changed each 3 days. After 10 days culture, the
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Figure 6. ENTPD5 Promotes ATP Hydrolysis and Glycolysis In Vivo
(A) Lactate in the culture media of PTEN+/ and PTEN/ MEF cells (columns 4 and 5) as well as PTEN+/ MEF clones stably transfected with vector control
(column 1) or Flag-tagged mouse ENTPD5 (column 2, clone 1 and column 3, clone 2, as used in Figure 2C) was measured as described in the Extended
Experimental Procedures, and the value was normalized to total protein amount.
(B) Lactate in the culture media of ENTPD5 knockdown and rescue cell lines was measured as in (A) except pretreatment with or without Dox for 2 days.
(C)PTEN+/ andPTEN/MEFwere deprived of glucose for indicated time periods, and intracellular ATPwas determined as described in Extended Experimental
procedures.
(D) The intracellular ATP was measured 1 hr after glucose starvation on ENTPD5 knockdown and rescue cell lines as in (B).
(E) ENTPD5 was knocked down as in (B), and the intracellular fructose-6-phosphate (left) and fructose-1,6-bisphosphate (right) were separated and quantified by
HPLCmass spectrometry (ABI 3200 Q TRAP LC/MS/MS Systems). The relative amount of metabolite is normalized to total ion count (TIC). All experiments were
repeated at least two times, and the error bar represents standard deviation.
See also Figure S4 and Figure S5.ENTPD5 Is Important for Cancer Cell Growth
To verify the functional significance of ENTPD5 expression in
human cancer cells, we generated a cell line from the original
LNCaP cells in which an shRNA against human ENTPD5 could720 Cell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc.be induced by Dox. In these cells, knockdown of ENTPD5 by
adding Dox to the culture media also lowered N-glycosylation
(Figure 7C, comparing lanes 7 and 8, 9 and 10, and 11 and 12)
and induced BiP expression (Figure 7C, lanes 8, 10, and 12).
These phenotypes were rescued by the expression of a wild-
type shRNA-resistant ENTPD5 transgene, but not by the active
site mutant ENTPD5 (Figure 7C, lanes 13–24). Several growth
factor receptors were also checked in these cell lines after Dox
treatment. As shown in Figure 7D, EGFR and Her2/ErbB-2
were significantly down, and IGFRbwas slightly down (Figure 7D,
lanes 1–4). They were restored to the normal level by the expres-
sion of shRNA-resistant ENTPD5 transgene (Figure 7D, lanes 5
and 6), but not the active site mutant (Figure 7D, lanes 7 and
8). Consistently, when the cell number was measured after
4 day knockdown of ENTPD5, only about half of LNCaP cells
were there, compared to a control knockdown cell line, and
the defect was rescued by expression of wild-type ENTPD5
transgene, but not active site mutant (Figure 7E).
To test whether knocking down ENTPD5 in LNCaP cells also
has an effect on their growth in vivo, we implanted the LNCaP
cells bearing a Dox-inducible shRNA targeting ENTPD5 in matri-
gel in nude mice. As a control, LNCaP cells with a Dox-inducible
shRNA targeting GFP were also implanted. After the xenograft
tumors reached the size of 500 mm3, a cohort of seven mice
were fed with Dox-containing water. The level of ENTPD5 in
these tumors was measured after 6 weeks. Compared with
mice fed with normal water, the ENTPD5 levels in ENTPD5-tar-
geting shRNA containing tumors from mice fed with Dox-con-
taining water were significantly lower except in one mouse
(Figure 7F). Whereas ENTPD5-targeting shRNA containing
tumors in mice fed with normal water continued to grow, the
tumors inmice fedwith Dox-containing water shrank (Figure 7G).
Amazingly, when these tumor samples were analyzed under
a microscope after fixing and staining with hematoxylin and
eosin, there were very few tumor cells left in the matrigel in
tumors grown in Dox-fed mice, whereas in mice fed with normal
water, the matrigel was filled with tumor cells (Figure 7H). The
GFP shRNA-containing tumors did not respond to Dox treatment
and continued to grow during the period of experiment.
DISCUSSION
ENTPD5 Is an Important Link in the PI3K/PTEN
Signaling Loop
The experimental data reported here identify ENTPD5, an ER
UDPase, as an important link in the PI3K/PTEN/AKT signaling
loop. We reason that ENTPD5 upregulation is important for
AKT-activated cells to cope with elevated translational activity
that generates more nascent polypeptide chains destined for
the ER.
ENTPD5 is a member of the ectonucleoside triphosphate
diphosphohydrolase family, which consists of seven other
members (reviewed by Robson et al., 2006). ENTPD 1–3
(CD39, CD39L1, and CD39L3) are typical ectoenzymes, whereas
the other fivemembers have a predominant intracellular localiza-
tion including ER, Golgi apparatus, and lysosomal/auto-
phagic vacuoles. The functions of these organelle-associated
ENTPDases are still largely unexplored, but judging by their loca-
tion and substrate preference, it would not be surprising if they all
turn out to regulate protein glycosylation.
Among members of this group of enzymes, however, ENTPD5
is the only intracellular ENTPDase that is transcriptionally upre-gulated in PTEN null cells (Figure S1). The mRNA of an extracel-
luar ENTPDase, ENTPD2, although expressed at a much lower
level than ENTPD5, was also elevated in PTEN null cells (Fig-
ure S1). The significance of such is unknown.
ENTPD5 Contributes to Warburg Effect
One of the surprising findings reported here is how quickly ATP
can be consumed as a result of ENTPD5 upregulation. One
naturally raised question is where the extra consumed ATP
comes from. After measuring both oxygen consumption and
lactate generation, we found that the lactate production was
elevated in these PTEN null cells, whereas oxygen consumption
did not change (Figure 6A and Figure S4). When ENTPD5 was
knocked down, higher lactate production returned to normal
(Figure 6B). Moreover, simply ectopically expressing ENTPD5
in PTEN heterozygous MEF elevated their lactate production
(Figure 6A). These results indicate that ENTPD5 is a critical player
in causing the Warburg effect, i.e., elevated lactate production
under aerobic conditions, in these PTEN null cells.
In addition to being part of the activation loop for AKT that
promotes glucose uptake into cells (Kohn et al., 1996; Plas
et al., 2001), a major effect of ENTPD5 on glycolysis might be
its ability to generate ADP/AMP through the aid of CMPK1 and
AK1. Elevated AMP levels (and to a lesser extent, ADP) activate
phosphofructokinase and inhibit fructose diphosphatase to drive
glycolysis and prevent gluconeogenesis, resulting in higher
lactate production (Gevers and Krebs, 1966). Consistently, the
fructose-1,6-bisphosphate level dropped to a much lower level
than that of fructose-6-phosphate when the ENTPD5 in PTEN
null cells was knocked down (Figure 6E).
In addition to UDP, ENTPD5 also use GDP as a substrate and
hydrolyze it to GMP (Figure 3A and Figure S3). It is interesting to
note that GDP-conjugated sugars are another group of major
substrates for glycosylation. The significance of hydrolyzing
GDP by ENTPD5 is not clear because it is believed that GDP
sugars are transferred to proteins in the Golgi.
ENTPD5 Is Potentially an Anticancer Target
The current study highlighted ENTPD5 as a critical link in the
PI3K/PTEN pathway that promotes cell growth and survival,
a pathway that is often activated in cancer cells. We saw good
correlation between ENTPD5 expression and AKT activation in
both cultured prostate cancer cell lines and primary human pros-
tate carcinoma samples (Figures 7A and 7B and Figures S6 and
S7). Therefore, inhibition of this enzyme, similar to knockdown,
can potentially generate benefits for anticancer activity. It should
inducemore severe ER stress in cancer cells with active AKT due
to higher protein traffic through the secretory pathway. It may
cause synthetic lethality in these cells, which otherwise maintain
survival advantage and resistance to common anticancer drugs.
It will also lower many growth factor receptors on the cell surface
due to their high N-glycosylation nature, a phenomenon that may
reflect the evolutionary connection between fast growth and
nutrient availability in mammalian cells (Lau et al., 2007). Among
such receptors, EGFR, Her2/ErB2, and IGFR levels were down
after ENTPD5 knockdown (Figure 5 and Figure 7), whereas
a nongrowth-promoting TGFb receptor did not change (data
not shown).Cell 143, 711–724, November 24, 2010 ª2010 Elsevier Inc. 721
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Figure 7. Knockdown of ENTPD5 in LNCaP Cells Decreases Glycosylation, Expression of Cell Surface Receptors, and Tumor Progression
(A) Aliquots of 20 mg of total cell extracts from indicated cell lines were subjected to 10% SDS-PAGE followed by western blotting analysis using antibodies as
indicated.
(B) Immunohistochemical staining for ENTPD5 (a and c) and pAKT (b and d) in adjacent sections of a human prostatic carcinoma sample (a/b 103 and c/d 203
lenses). Scale bar, 200 mM (a and b); 100 mM (c and d). Arrows indicate tumor.
(C) Inducible ENTPD5 knockdown and rescue stable cell lines were treated with or without Dox (0.0625 mg/ml) for indicated time periods. Aliquots of 10 mg of total
cell extracts were subjected to 10% SDS-PAGE for western blotting analysis of ENTPD5, BiP, glycosylated proteins (PHA blot), and b-actin. Asterisk indicates
decreased glycosylated proteins.
(D) Indicated cell lines were plated and treated with or without Dox for 6 days, total cell lysates were prepared, and aliquots of 10 mg protein were subjected to
SDS-PAGE followed by western blotting analysis using indicated antibodies.
(E) Indicated cells (1 3 104) were seeded in 96-well plates and then treated with and without Dox (1 mg/ml) for 4 days. Cell contents were measured.
(F–H) 2 3 106 LNCaP cells with Dox-inducible shRNA target GFP or ENTPD5 were injected subcutaneously into the flank of nude mice as described in the
Extended Experimental Procedures. When the tumors reached a volume of 500 mm3, mice were fed with normal or Dox-containing water.
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Chronic inhibition of ENTPD5may cause liver andmale fertility
defects because mice with ENTPD5 deficiency show hepatop-
athy and aspermia (Read et al., 2009). These defects in mice,
however, only become obvious after 1 year of age. Given the
poor prognosis of PI3K/PTEN mutations in human cancers and
potential synthetic lethal effect of AKT activation and ENTPD5
inhibition, developing ENTPD5 inhibitors for cancer therapy
may be a worthwhile pursuit.
EXPERIMENTAL PROCEDURES
General Reagents and Methods
General chemicals are from Sigma unless otherwise described. We obtained
a-P32-labeled ATP from GE Healthcare. All other nucleotides are from Sigma.
Nonhydrolyzable uracil and guanine nucleotide analogs are from Gena Biosci-
ence (Germany). HRP-conjugated E-type PHA is from USBioLogical
(Ca#P3371-25). Puromycin, blasticidin, and hygromycin, which are used for
establishment and maintenance of stable cell lines, are purchased from Inviv-
ogen (Ca#ant-pr-1, ant-bl-1, and ant-hg-1, respectively). G418 is from Calbio-
chem (Ca#345810). The sources of antibodies used are listed in the Extended
Experimental Procedures.
Cell Culture
PTEN+/ and PTEN/ MEF cells are established previously (Stambolic et al.,
1998). The sources of all other cell lines used and their culture conditions are
described in the Extended Experimental Procedures.
In Vitro ATP Hydrolysis Assay
The ATP hydrolysis assays were carried out by incubation-indicated cell
extracts or purified enzymes with a-P32-ATP and were analyzed by thin layer
chromatography (TLC). The detailed method was described in the Extended
Experimental Procedures.
Purification of ENTPD5 and CMPK
All purification steps were carried out at 4C. All chromatography steps were
carried out using an automatic fast protein liquid chromatography (FPLC)
station (Pharmacia). The details of purification methods were described in
the Extended Experimental Procedures.
ENTPD5 Expression and ENTPD5 shRNA Constructs
All ENTPD5 expression and shRNA constructs were made as described in the
Extended Experimental Procedures.
Preparation of Recombinant ENTPD5, CMPK1, and Adenylate
Kinase
Human ENTPD5 recombinant protein was generated using Bac-to-Bac Bacu-
lovirus Expression Systems (Invitrogen Cat# 10359-016). Human CMPK1 and
AK1 were generated by bacterial expression. The details of methods were
described in the Extended Experimental Procedures.
Measurement of Lactate Production in Cell Culture Medium
We purchased Lactate Assay kit from Biovision (Cat#K627-100). Measure-
ment of Lactate concentration in cell culture medium was performed accord-
ing the manufacturer’s instruction and described in detail in the Extended
Experimental Procedures.(F) Tumors lysates were extracted after 6 weeks, and aliquots of 20 mg of protein w
was stained with Ponceau S staining (bottom) followed by western blotting analy
(G) Time course of tumor shrinkage caused by ENTPD5 knocking down. Tumor
Extended Experimental Procedures. Each group consisted of seven mice. The v
(H) Hematoxylin and eosin staining of resected tumors. (Left) Scale bar, 500 um.
See also Figure S6 and Figure S7.Measurement of Intracellular Fructose-6-P and Fructose-1,6-2P
The preparation and measurement of these two phosphosugars by LC-Mass
were described in the Extended Experimental Procedures.
Cell Survival Assay
Cell survival analysis was performed using the Cell Titer-Glo Luminescent Cell
Viability Assay kit (Promega) following manufacturer’s instruction with minor
modification. In brief, 25 ml of Cell Titer-Glo reagent was added to the cell
culture medium. Cells were placed on a shaker for 10 min and were then
incubated at room temperature for an additional 10 min. Luminescent reading
was carried on a Tecan SPECTRAFluor Plus reader (Tecan).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at doi:10.1016/j.
cell.2010.10.010.
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